Posterior Subtenon Autologous Platelet-Rich Plasma in Non-Arteritic Anterior Ischemic Optic Neuropathy: An Exploratory Randomized Study

Introduction: To evaluate the short-term functional, structural, and safety outcomes of posterior sub-Tenon autologous platelet-rich plasma (PRP) injection in acute nonarteritic anterior ischemic optic neuropathy (NAION). Methods: This prospective, exploratory, open-label randomized study included 39 patients with acute NAION allocated to posterior sub-Tenon PRP injection (n=21) or observation (n=18). PRP was administered at baseline and Weeks 3 and 6. Best-corrected visual acuity (BCVA), global retinal nerve fiber layer (RNFL) thickness, visual field mean deviation (MD), and visual field index (VFI) were assessed over 16 weeks. Baseline-adjusted linear mixed-effects models using available post-baseline measurements were used for longitudinal analyses. Exploratory Week 16 comparisons were performed using baseline-adjusted ANCOVA. Results: The 39 randomized participants had a mean age of 59.28 ± 9.50 years, and 26 (66.7%) were male. Thirty-one participants (15 PRP and 16 control) contributed to the longitudinal analyses. No significant group-by-time interaction was observed for BCVA (p=0.094), RNFL thickness (p=0.655), MD (p=0.124), or VFI (p=0.559). Significant overall time effects were observed for BCVA (p=0.006) and RNFL thickness (p<0.001), but changes did not differ significantly between groups. Baseline-adjusted Week 16 comparisons also showed no significant between-group differences in BCVA, RNFL thickness, MD, or VFI. No serious ocular or systemic adverse events were documented. Discussion: Posterior sub-Tenon autologous PRP did not show evidence of a short-term functional or structural advantage over observation in acute NAION. Interpretation is limited by the small sample size, incomplete follow-up, and absence of sham control and masking. Larger, adequately powered randomized trials with standardized PRP characterization and systematic safety monitoring are warranted. Clinical Trial Registration: ClinicalTrials.gov: NCT07330713 (retrospectively registered on December 28, 2025).

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-20
DOI
https://doi.org/10.21203/rs.3.rs-11526988/v1
Primary Topic
Glaucoma and retinal disorders
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Posterior Subtenon Autologous Platelet-Rich Plasma in Non-Arteritic Anterior Ischemic Optic Neuropathy: An Exploratory Randomized Study

Selim Doğanay, Gamze Uçan Gündüz, Güven Özkaya, Derya Doğanay et al.
Research Square
Glaucoma and retinal disorders
preprint

Posterior Subtenon Autologous Platelet-Rich Plasma in Non-Arteritic Anterior Ischemic Optic Neuropathy: An Exploratory Randomized Study

Selim Doğanay, Gamze Uçan Gündüz, Güven Özkaya, Derya Doğanay, Sema Nizam Tekcan, Emine Rabia Koç
preprint en

Abstract

Introduction: To evaluate the short-term functional, structural, and safety outcomes of posterior sub-Tenon autologous platelet-rich plasma (PRP) injection in acute nonarteritic anterior ischemic optic neuropathy (NAION). Methods: This prospective, exploratory, open-label randomized study included 39 patients with acute NAION allocated to posterior sub-Tenon PRP injection (n=21) or observation (n=18). PRP was administered at baseline and Weeks 3 and 6. Best-corrected visual acuity (BCVA), global retinal nerve fiber layer (RNFL) thickness, visual field mean deviation (MD), and visual field index (VFI) were assessed over 16 weeks. Baseline-adjusted linear mixed-effects models using available post-baseline measurements were used for longitudinal analyses. Exploratory Week 16 comparisons were performed using baseline-adjusted ANCOVA. Results: The 39 randomized participants had a mean age of 59.28 ± 9.50 years, and 26 (66.7%) were male. Thirty-one participants (15 PRP and 16 control) contributed to the longitudinal analyses. No significant group-by-time interaction was observed for BCVA (p=0.094), RNFL thickness (p=0.655), MD (p=0.124), or VFI (p=0.559). Significant overall time effects were observed for BCVA (p=0.006) and RNFL thickness (p<0.001), but changes did not differ significantly between groups. Baseline-adjusted Week 16 comparisons also showed no significant between-group differences in BCVA, RNFL thickness, MD, or VFI. No serious ocular or systemic adverse events were documented. Discussion: Posterior sub-Tenon autologous PRP did not show evidence of a short-term functional or structural advantage over observation in acute NAION. Interpretation is limited by the small sample size, incomplete follow-up, and absence of sham control and masking. Larger, adequately powered randomized trials with standardized PRP characterization and systematic safety monitoring are warranted. Clinical Trial Registration: ClinicalTrials.gov: NCT07330713 (retrospectively registered on December 28, 2025).

Research Square
Bursa Uludağ Üni̇versi̇tesi̇ (TR), S.B.Ü. Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi (TR)
Good health and well-being
Glaucoma and retinal disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon